# Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

> **NCT04627428** · PHASE1,PHASE2 · RECRUITING · sponsor: **Luxa Biotechnology, LLC** · enrollment: 18 (estimated)

## Conditions studied

- Dry Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** RPESC-RPE-4W

## Key facts

- **NCT ID:** NCT04627428
- **Lead sponsor:** Luxa Biotechnology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-05
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627428, "Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04627428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*